NMRA
Neumora Therapeutics, Inc.
NASDAQ: NMRA · HEALTHCARE · BIOTECHNOLOGY
$2.25
+0.00% today
Updated 2026-04-29
Market cap
$405.57M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.45
Dividend yield
—
52W range
$1 – $4
Volume
1.1M
Neumora Therapeutics, Inc. (NMRA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-26.76M | $-26.76M | $-75.42M | $-114.90M | $-163.28M | $-182.94M | $-206.44M |
| Capital expenditures | $1.30M | $1.30M | $817000.00 | $511000.00 | $117000.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | — | $1.68M | $4.27M | $8.30M | $17.24M | $39.99M | $29.88M |
| Free cash flow | $-28.06M | $-28.06M | $-76.24M | $-115.41M | $-163.40M | $-182.94M | $-206.44M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |